Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Rafael Henrique/SOPA Images/LightRocket via Getty Images

Johnson & Johnson has begun phase 3 trials in the U.S. for its one-shot coronavirus vaccine, with plans to enroll the most participants of any trial yet.

The big picture: Johnson & Johnson's vaccine has several advantages over its competitors that make it a promising option for mass distribution: The company is initially testing it as one dose and it does not have to be frozen for storage.

  • The Johnson & Johnson phase 3 trials will enroll 60,000 participants.

Between the lines: There's an increased scrutiny on the safety of any coronavirus vaccine that comes to market, and the FDA is planning on toughening the requirements for emergency authorization.

  • “With a larger trial, it also increases the safety data set,” said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, according to the Washington Post. “Safety has been a lot in the public eye, and increasing the size of trials increases the safety data set as well.”
  • It is the 4th vaccine in the U.S. to enter Phase 3.

Go deeper

Updated Feb 23, 2021 - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: Axios-Ipsos poll: 1 in 3 Americans know someone who died from COVID-19 — Axios-Ipsos poll: Biden's window of opportunity on COVID — Nursing home COVID cases have drastically declinedU.S. death toll tops 500,000.
  2. Vaccine: Pfizer and Moderna expect to double vaccine shipments by spring — Fast-spreading misinformation on COVID vaccine and infertility worries health experts — Modified vaccines for variants would not require large clinical trials, FDA says.
  3. Economics: Small businesses say even second round of PPP loans not enoughU.S. growth expectations are going through the roof.
  4. Local: Denver breaks from Colorado's vaccine plan Twin Cities and some Midwest metros fare better economically than rest of U.S. — Federal vaccine distribution arriving in Tampa.
  5. World: Boris Johnson unveils roadmap to fully reopen England's economy by June.
Dec 31, 2020 - Health

U.S. set to end 2020 with just over 3 million vaccine doses administered

A healthcare worker hands Patrick Range, Sr., 88, a vaccination card after giving him the Pfizer/BioNTech vaccine at Jackson Memorial Hospital in Miami on Dec. 30. Photo: Marco Bello/Anadolu Agency via Getty Images

Americans received just over 3 million initial doses of coronavirus vaccines from Moderna and Pfizer-BioNTech in the 19 days following first shipments, according to a Bloomberg tally of government websites and CDC data.

Why it matters: It's far below Operation Warp Speed's goal of administering 20 million doses by the end of the year, raising concerns about how long it may be until enough people are vaccinated in the U.S. for life to return to normal.

Dec 31, 2020 - Health

China approves state-owned Sinopharm vaccine

Sinopharm vaccine. Photo Illustration: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

Health regulators in China said Thursday they have approved the country's first homegrown COVID-19 vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use, AP reports.

Why it matters: Like the vaccine developed by AstraZeneca and Oxford University, Sinopharm's shot is said to be cheaper and easier to store than Pfizer or Moderna's vaccines.